The estimated Net Worth of Emily Transcend Partners Op... is at least $1.24 Milhão dollars as of 16 August 2022. Emily Op owns over 789,473 units of In8 Bio stock worth over $1,244,278 and over the last 3 years Emily sold INAB stock worth over $0.
Emily has made over 2 trades of the In8 Bio stock since 2021, according to the Form 4 filled with the SEC. Most recently Emily bought 789,473 units of INAB stock worth $1,499,999 on 16 August 2022.
The largest trade Emily's ever made was buying 789,473 units of In8 Bio stock on 16 August 2022 worth over $1,499,999. On average, Emily trades about 444,737 units every 189 days since 2021. As of 16 August 2022 Emily still owns at least 4,111,958 units of In8 Bio stock.
You can see the complete history of Emily Op stock trades at the bottom of the page.
Emily's mailing address filed with the SEC is 10 ORINDA VIEW ROAD10 ORINDA VIEW ROAD, , ORINDAORINDA, CACA, 9456394563.
Over the last 3 years, insiders at In8 Bio have traded over $0 worth of In8 Bio stock and bought 5,038,673 units worth $10,468,296 . The most active insiders traders include Aaron G.L.Bios Equity Partn..., Leslie W.Bios Fund Ii Nt, L..., eEmily Transcend Partners Op.... On average, In8 Bio executives and independent directors trade stock every 32 days with the average trade being worth of $63,860. The most recent stock trade was executed by Jeremy R. Graff on 13 September 2023, trading 2,500 units of INAB stock currently worth $2,375.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
In8 Bio executives and other stock owners filed with the SEC include: